Summary of Study ST000168
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000146. The data can be accessed directly via it's Project DOI: 10.21228/M83G6X This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
| Study ID | ST000168 |
| Study Title | Effect of Insulin Sensitizer Therapy on Amino Acids and Their Metabolites |
| Study Type | drug + time course |
| Study Summary | We previously reported the overall study design for the parent study [29]. The current report primarily examines the effect of three months of insulin sensitizer therapy on plasma concentrations of BCAA, AAA, and AA metabolites in overweight/obese adults with fasting hyperglycemia, defined as either impaired fasting glucose or untreated diabetes [29]. Briefly, 25 drug naïve, Northern European American participants with fasting blood glucose concentrations of 108180 mg/dL were randomized to receive either 45 mg of pioglitazone per day plus 1 g of metformin twice per day (n = 12) or placebo (n = 13) for 12 weeks. We chose metformin based on its proven effect on hepatic insulin sensitivity and pioglitazone based on its effect on peripheral insulin sensitivity. Current use of hypoglycemic medications excluded participants from the present study. |
| Institute | Mayo Clinic |
| Department | Endocrinology |
| Laboratory | Sree Nair |
| Last Name | Nair |
| First Name | Sreekumaran |
| Dasari.Surendra@mayo.edu | |
| Submit Date | 2015-05-21 |
| Num Groups | 2 |
| Total Subjects | 27 |
| Raw Data Available | No |
| Analysis Type Detail | LC-MS |
| Release Date | 2015-06-28 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
| Project ID: | PR000146 |
| Project DOI: | doi: 10.21228/M83G6X |
| Project Title: | Effect of Insulin Sensitizer Therapy on Amino Acids and Their Metabolites |
| Project Summary: | Aims Prior studies have reported that elevated concentrations of several plasma amino acids (AA), particularly branched chain (BCAA) and aromatic AA predict the onset of type 2 diabetes. We sought to test the hypothesis that circulating BCAA, aromatic AA and related AA metabolites decline in response to the use of insulin sensitizing agents in overweight/obese adults with impaired fasting glucose or untreated diabetes. Methods We performed a secondary analysis of a randomized, double-blind, placebo, controlled study conducted in twenty five overweight/obese (BMI ~ 30 kg/m2) adults with impaired fasting glucose or untreated diabetes. Participants were randomized to three months of pioglitazone (45 mg per day) plus metformin (1000 mg twice per day, N = 12 participants) or placebo (N = 13). We measured insulin sensitivity by the euglycemic-hyperinsulinemic clamp and fasting concentrations of AA and AA metabolites using ultra-pressure liquid chromatography tandem mass spectrometry before and after the three-month intervention. Results Insulin sensitizer therapy that significantly enhanced insulin sensitivity reduced 9 out of 33 AA and AA metabolites measured compared to placebo treatment. Moreover, insulin sensitizer therapy significantly reduced three functionally clustered AA and metabolite pairs: i) phenylalanine/tyrosine, ii) citrulline/arginine, and iii) lysine/?-aminoadipic acid. Conclusions Reductions in plasma concentrations of several AA and AA metabolites in response to three months of insulin sensitizer therapy support the concept that reduced insulin sensitivity alters AA and AA metabolites. |
| Institute: | Mayo Clinic |
| Department: | Endocrinology |
| Laboratory: | Sree Nair |
| Last Name: | Nair |
| First Name: | Sreekumaran |
| Email: | Dasari.Surendra@mayo.edu |
